collection
MENU ▼
Read by QxMD icon Read
search

LES

shared collection
96 papers 25 to 100 followers
https://www.readbyqxmd.com/read/29642752/lupus-myocarditis-a-single-center-experience-and-a-comparative-analysis-of-observational-cohort-studies
#1
J Tanwani, K Tselios, D D Gladman, J Su, M B Urowitz
Background Lupus myocarditis (LM) is reported in 3-9% of patients with systemic lupus erythematosus (SLE) but limited evidence exists regarding optimal treatment and prognosis. This study aims to describe LM in a defined lupus cohort as compared with the existing literature. Patients and methods Patients with LM were identified from the University of Toronto Lupus Clinic database. Diagnosis was based on clinical manifestations and electrocardiographic, imaging, and biochemical criteria. Demographic, clinical, diagnostic and therapeutic variables and outcomes were collected in a standardized data retrieval form...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29629608/intravenous-pulses-of-methylprednisolone-to-treat-flares-of-immune-mediated-diseases-how-much-how-long
#2
A Danza, I Borgia, J I Narváez, A Baccelli, C Amigo, M Rebella, V Domínguez
Introduction Glucocorticoids are widely used in the treatment of immune-mediated diseases. Despite their widespread use, details on dosing, effectiveness and adverse effects are yet to be determined. Objective To know the current use of methylprednisolone (MTP) in the management of immune-mediated conditions, evaluating the relationship among doses, therapeutic response and adverse effects. Methodology A multicenter retrospective cohort study was designed, including patients who received intravenous pulses of MTP between 1 January 2013 and 12 December 2015 in three different hospitals in Uruguay...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29559714/the-non-haemostatic-role-of-platelets-in-systemic-lupus-erythematosus
#3
REVIEW
Petrus Linge, Paul R Fortin, Christian Lood, Anders A Bengtsson, Eric Boilard
Dysregulation of lymphocyte function, accumulation of autoantibodies and defective clearance of circulating immune complexes and apoptotic cells are hallmarks of systemic lupus erythematosus (SLE). Moreover, it is now evident that an intricate interplay between the adaptive and innate immune systems contributes to the pathogenesis of SLE, ultimately resulting in chronic inflammation and organ damage. Platelets circulate in the blood and are chiefly recognized for their role in the prevention of bleeding and promotion of haemostasis; however, accumulating evidence points to a role for platelets in both adaptive and innate immunity...
March 21, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29559718/type-i-interferon-in-rheumatic-diseases
#4
REVIEW
Theresa L Wampler Muskardin, Timothy B Niewold
The type I interferon pathway has been implicated in the pathogenesis of a number of rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis, systemic sclerosis, and rheumatoid arthritis. In normal immune responses, type I interferons have a critical role in the defence against viruses, yet in many rheumatic diseases, large subgroups of patients demonstrate persistent activation of the type I interferon pathway. Genetic variations in type I interferon-related genes are risk factors for some rheumatic diseases, and can explain some of the heterogeneity in type I interferon responses seen between patients within a given disease...
March 21, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29546774/the-ratio-of-erythrocyte-sedimentation-rate-to-c-reactive-protein-is-useful-in-distinguishing-infection-from-flare-in-systemic-lupus-erythematosus-patients-presenting-with-fever
#5
E Littlejohn, W Marder, E Lewis, S Francis, J Jackish, W J McCune, E C Somers
Background Both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be elevated in systemic lupus erythematosus (SLE) flare and infection, and are therefore of limited utility for distinguishing between the two conditions in febrile SLE patients. Methods A medical records review of hospitalizations (1997-2006) of SLE patients in the Michigan Lupus Cohort was performed. Eligible hospitalizations were those in which patients presented with a temperature of >100.3°F or with subjective fevers as a presenting complaint at admission...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29288864/assessment-of-subclinical-atherosclerosis-in-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis
#6
Pauline Henrot, Jennifer Foret, Thomas Barnetche, Estibaliz Lazaro, Pierre Duffau, Julien Seneschal, Thierry Schaeverbeke, Marie-Elise Truchetet, Christophe Richez
OBJECTIVES: To determine whether subclinical atherosclerosis is increased in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, using carotid intima-media thickness (CIMT), carotid plaque (CP) presence or flow-mediated dilatation (FMD). METHODS: A systematic literature search was performed using MedLine, Embase and Cochrane databases. Two reviewers independently screened the articles to identify studies that compared the rates of atherosclerosis in SLE patients versus healthy controls...
March 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29481673/macrophage-activation-syndrome-in-adults-recent-advances-in-pathophysiology-diagnosis-and-treatment
#7
Stuart J Carter, Rachel S Tattersall, Athimalaipet V Ramanan
Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome, which if not promptly treated, can lead rapidly to critical illness and death. HLH is termed macrophage activation syndrome (MAS) when associated with rheumatic disease (where it is best characterized in systemic JIA) and secondary HLH (sHLH) when associated with other triggers including malignancy and infection. MAS/sHLH is rare and coupled with its mimicry of other conditions, is underrecognized. These inherent challenges can lead to diagnostic and management challenges in multiple medical specialties including haematology, infectious diseases, critical care and rheumatology...
February 21, 2018: Rheumatology
https://www.readbyqxmd.com/read/29440000/assay-variation-in-the-detection-of-antinuclear-antibodies-in-the-sera-of-patients-with-established-sle
#8
David S Pisetsky, Diane M Spencer, Peter E Lipsky, Brad H Rovin
OBJECTIVE: The expression of antinuclear antibodies (ANA) is considered almost constant in systemic lupus erythematosus (SLE), although recent experience has suggested that many subjects with SLE considered for clinical trials are ANA negative at screening. The objective of this study is to determine whether assay variation can influence ANA detection in patients with established SLE. METHODS: Sera from 103 patients with established SLE were tested using three different immunofluorescence assays (IFA) for ANA determination...
February 9, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29451069/arthritis-and-use-of-hydroxychloroquine-associated-with-a-decreased-risk-of-macrophage-activation-syndrome-among-adult-patients-hospitalized-with-systemic-lupus-erythematosus
#9
E M Cohen, K D'Silva, D Kreps, M B Son, K H Costenbader
Background Macrophage activation syndrome (MAS) is an uncommon but serious complication of systemic lupus erythematosus (SLE). We aimed to identify factors associated with MAS among adult hospitalized SLE patients. Methods Within the Brigham and Women's Hospital (BWH) Lupus Center Registry, we identified adult SLE patients > age 17 who had been hospitalized from 1970 to 2016, with either ferritin > 5000 ng/ml during admission or "macrophage activation syndrome" or "MAS" in discharge summary...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29371202/complement-activation-predicts-adverse-pregnancy-outcome-in-patients-with-systemic-lupus-erythematosus-and-or-antiphospholipid-antibodies
#10
Mimi Y Kim, Marta M Guerra, Elianna Kaplowitz, Carl A Laskin, Michelle Petri, D Ware Branch, Michael D Lockshin, Lisa R Sammaritano, Joan T Merrill, T Flint Porter, Allen Sawitzke, Anne M Lynch, Jill P Buyon, Jane E Salmon
OBJECTIVE: Studies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. METHODS: The PROMISSE Study enrolled pregnant women with SLE and/or aPL antibodies (n=487) and pregnant healthy controls (n=204) at <12 weeks gestation and evaluated them monthly...
April 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29245186/endothelial-dysfunction-in-early-systemic-lupus-erythematosus-patients-and-controls-without-previous-cardiovascular-events
#11
Mara Taraborelli, Edoardo Sciatti, Ivano Bonadei, Vincenzo Terlizzi, Micaela Fredi, Roberta Zani, Giovanni Cancarini, Angela Tincani, Franco Franceschini, Enrico Vizzardi, Ilaria Cavazzana
OBJECTIVES: To assess the prevalence and risk factors for endothelial dysfunction detected by peripheral artery tonometry in systemic lupus erythematosus patients with early disease without cardiovascular disease and risk factors. METHODS: All the consecutive adult lupus patients, with a disease duration less than 5 years, seen in our Hospital from December 2014 to March 2016 were considered. We excluded patients with any history of cardiovascular disease or risk factors possibly affecting peripheral artery tonometry...
December 15, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29148424/effect-of-the-metabolic-syndrome-on-organ-damage-and-mortality-in-patients-with-systemic-lupus-erythematosus-a-longitudinal-analysis
#12
Chi Chiu Mok, Sau Mei Tse, Kar Li Chan, Ling Yin Ho
OBJECTIVES: To study the effect of the metabolic syndrome (MetS) on organ damage and mortality in patients with SLE. METHODS: Consecutive patients who fulfilled ≥4 ACR criteria for SLE were assessed for the MetS in October 2010. The MetS was defined by the updated joint consensus criteria, using the Asian criteria for central obesity. Longitudinal data on organ damage and mortality were retrieved. The association between MetS and new damage and mortality was studied by logistic regression...
October 18, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29224678/atherosclerosis-in-systemic-lupus-erythematosus
#13
REVIEW
Sara Croca, Anisur Rahman
Cardiovascular disease (CVD), comprising coronary heart disease and stroke, is one of the most important causes of death in patients with systemic lupus erythematosus (SLE). The risks of developing both clinical CVD and sub-clinical atherosclerosis are increased in patients with SLE. This increase is not fully explained by traditional cardiovascular risk factors such as smoking, hypertension and elevated cholesterol, and it is believed that immune dysfunction also contributes to CVD risk in SLE. In particular, recent studies have shown that abnormalities in both serum lipid profile and the autoantibody and T lymphocyte response to lipids may play a role in development of atherosclerosis...
June 2017: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/29108828/can-we-manage-lupus-nephritis-without-chronic-corticosteroids-administration
#14
REVIEW
Liz Lightstone, Andrea Doria, Hannah Wilson, Frank L Ward, Maddalena Larosa, Joanne M Bargman
The outcome of lupus nephritis (LN) has changed since the introduction of glucocorticoids (GCs), which dramatically reduced the mortality related to one of the most severe complications of systemic lupus erythematosus (SLE). Since the 1950's, other immunosuppressants, including biologic drugs (i.e. rituximab) have aided in maintaining remission, preserving kidney function, but not preventing treatment-related toxicity. GCs still remain the cornerstone in the treatment of SLE, including LN, and they are widely used in clinical practice...
January 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29108824/can-we-withdraw-immunosuppressants-in-patients-with-lupus-nephritis-in-remission-an-expert-debate
#15
REVIEW
Gabriella Moroni, Mariele Gatto, Francesca Raffiotta, Valentina Binda, Eleni Frangou, Liz Lightstone, Dimitrios T Boumpas
Lupus nephritis (LN) treatment requires an initial intensive period of therapy followed by a long-term maintenance treatment in order to stabilize disease control and eventually reach renal remission. In this section, Authors discuss the feasibility of safely lowering and even suspending maintenance therapy in LN patients having entered remission, highlighting hurdles in predicting the depth and durability of disease quiescence together with the need for minimizing potentially toxic therapies. Even though no firm conclusions can still be drawn, the treating physician has to find the wise balance between disease control and treatment-related drawbacks by following patients closely and recognizing as early as possible the ones who are likely to reach a deep and durable renal remission; there is consensus that is these are the only patients in whom a potential safe complete withdrawal can be foreseen so far...
January 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28192415/immune-regulation-by-glucocorticoids
#16
REVIEW
Derek W Cain, John A Cidlowski
Endogenous glucocorticoids are crucial to various physiological processes, including metabolism, development and inflammation. Since 1948, synthetic glucocorticoids have been used to treat various immune-related disorders. The mechanisms that underlie the immunosuppressive properties of these hormones have been intensely scrutinized, and it is widely appreciated that glucocorticoids have pleiotropic effects on the immune system. However, a clear picture of the cellular and molecular basis of glucocorticoid action has remained elusive...
April 2017: Nature Reviews. Immunology
https://www.readbyqxmd.com/read/28851621/pulmonary-arterial-hypertension-associated-with-systemic-lupus-erythematosus-results-from-the-french-pulmonary-hypertension-registry
#17
Eric Hachulla, Xavier Jais, Gaël Cinquetti, Pierre Clerson, Laurence Rottat, David Launay, Vincent Cottin, Gilbert Habib, Grégoire Prevot, Céline Chabanne, Eléna Foïs, Zahir Amoura, Luc Mouthon, Véronique Le Guern, David Montani, Gérald Simonneau, Marc Humbert, Vincent Sobanski, Olivier Sitbon
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE). METHODS: We identified all patients with SLE and PAH (SLE-PAH) who were enrolled in the French Pulmonary Hypertension Registry with a diagnosis confirmed by right heart catheterization (RHC). A control group of 101 patients with SLE without known PAH was selected from SLE expert centers participating in the Pulmonary Hypertension Registry. Survival was estimated by the Kaplan-Meier method...
January 2018: Chest
https://www.readbyqxmd.com/read/28794077/survival-in-adults-and-children-with-systemic-lupus-erythematosus-a-systematic-review-and-bayesian-meta-analysis-of-studies-from-1950-to-2016
#18
REVIEW
Maria G Tektonidou, Laura B Lewandowski, Jinxian Hu, Abhijit Dasgupta, Michael M Ward
OBJECTIVE: To determine trends in survival among adult and paediatric patients with systemic lupus erythematosus (SLE) from 1950 to the present. METHODS: We performed a systematic literature review to identify all published cohort studies on survival in patients with SLE. We used Bayesian methods to derive pooled survival estimates separately for adult and paediatric patients, as well as for studies from high-income countries and low/middle-income countries. We pooled contemporaneous studies to obtain trends in survival over time...
December 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28786768/primary-prevention-of-cardiovascular-disease-in-patients-with-systemic-lupus-erythematosus-case-series-and-literature-review
#19
S Fasano, D P Margiotta, L Navarini, L Pierro, I Pantano, A Riccardi, A Afeltra, G Valentini
Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Low-dose aspirin, hydroxychloroquine and statins have been suggested to play a prophylactic role of cardiovascular events. This study is devoted to reviewing the literature on the topic and assessing the effects of these drugs in preventing a first cardiovascular event in a two-centre Italian series. Methods A PubMed search on cardiovascular prevention in systemic lupus erythematosus was performed. Moreover, systemic lupus erythematosus patients admitted to two centres from 2000-2015, who at admission had not experienced any cardiovascular event, were investigated...
December 2017: Lupus
https://www.readbyqxmd.com/read/28675998/cardiovascular-and-pulmonary-manifestations-of-systemic-lupus-erythematosus
#20
Konstantinos Tselios, Murray B Urowitz
BACKGROUND: Systemic lupus erythematosus (SLE) is characterized by various clinical manifestations and immunologic abnormalities. Cardiovascular and respiratory system involvement are increasingly recognized as critical for patients' prognosis. In this review, current knowledge concerning diagnosis, pathogenesis and treatment of the cardiac and pulmonary lupus manifestations are discussed. METHOD: Review of the literature. RESULTS: Although pericarditis is the most frequent heart manifestation in the context of lupus, valvular disease and less often myocarditis may be detected...
2017: Current Rheumatology Reviews
label_collection
label_collection
6416
1
2
2017-07-23 00:21:13
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"